枸地氯雷他定联合布地奈德治疗鼻窦炎患者的效果  

Curative effect of desloratadine citrate combined with budesonide in patients with sinusitis

作　　者：陈雪松[1] 王雪松[1] 付伟伟 Chen Xuesong;Wang Xuesong;Fu Weiwei(E.N.T.Department,binzhou central hospital,binzhou 251700,china)

机构地区：[1]滨州市中心医院耳鼻咽喉科,山东251700

出　　处：《国际医药卫生导报》2021年第14期2170-2173,共4页International Medicine and Health Guidance News

摘　　要：目的探讨枸地氯雷他定联合布地奈德治疗鼻窦炎患者的效果。方法选取2018年2月至2020年2月本院收治的鼻窦炎患者86例,随机数字表法分为两组,各43例。对照组男25例,女18例,年龄(38.4±1.2)岁;研究组男26例,女17例,年龄(38.3±1.3)岁。对照组给予布地奈德治疗,研究组给予枸地氯雷他定联合布地奈德治疗。观察分析两组治疗效果、变态反应变化情况以及炎症因子水平。结果研究组治疗总有效率为93.0%(40/43),明显高于对照组65.1%(28/43),差异有统计学意义(χ^(2)=10.118,P<0.05)。治疗前,两组鼻窦炎患者变态反应比较,差异均无统计学意义(均P>0.05);治疗后,研究组血清总免疫球蛋白E(TIgE)、嗜酸性粒细胞阳离子蛋白(ECP)水平分别为(56.3±4.2)kU/L、(4.1±0.3)ng/L,均明显低于对照组(64.2±6.9)kU/L、(5.5±0.9)ng/L,差异均有统计学意义(均P<0.05)。治疗前,两组鼻窦炎患者炎症因子水平比较,差异均无统计学意义(均P>0.05);治疗后,研究组血清白细胞介素(IL)-6、高敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF)-α水平分别为(1.2±0.4)μg/L、(5.2±1.1)pg/ml、(2.8±0.3)ng/L,均低于对照组(2.8±0.8)μg/L、(10.3±2.1)pg/ml、(3.9±0.7)ng/L,差异均有统计学意义(均P<0.05)。结论对鼻窦炎患者应用枸地氯雷他定联合布地奈德治疗可有效增强治疗效果,使患者血清TIgE、ECP水平明显降低,并能对炎性反应起到一定的抑制作用,可推广使用。Objective To investigate the curative effect of desloratadine citrate combined with budesonide in patients with sinusitis.Methods A total of 86 patients with sinusitis in our hospital from February 2018 to February 2020 were selected and were divided into a study group and a control group with the random number table,43 cases in each group.In the control group,there were 25 males and 18 females,with an age of(38.4±1.2)years old;in the study group,there were 26 males and 17 females,with an age of(38.3±1.3)years old.The control group was treated with budesonide,and the study group was treated with desloratadine citrate combined with budesonide.The curative effects,allergic reactions,and inflammatory factors of the two groups were observed and analyzed.Results The total effective rate of the study group was 93.0%(40/43),which was significantly higher than 65.1%(28/43)of the control group(χ^(2)=10.118,P<0.05).Before the treatment,there were no statistically significant differences in the allergic reactions of sinusitis patients between the two groups(both P>0.05);after the treatment,serum total immunoglobulin E(TIgE)and eosinophilic cationic protein(ECP)levels of the study group were(56.3±4.2)kU/L and(4.1±0.3)ng/L respectively,which were significantly lower than those of the control group[(64.2±6.9)kU/L and(5.5±0.9)ng/L](both P<0.05).Before the treatment,there were no statistically significant differences in the levels of inflammatory factors between the two groups(all P>0.05);after the treatment,serum levels of interleukin(IL)-6,high-sensitivity C-reactive protein(hs-CRP),and tumor necrosis factor(TNF)-αin the study group were(1.2±0.4)μg/L,(5.2±1.1)pg/ml,and(2.8±0.3)ng/L,respectively,which were lower than those in the control group[(2.8±0.8)μg/L,(10.3±2.1)pg/ml,and(3.9±0.7)ng/L](all P<0.05).Conclusion The application of desloratadine citrate combined with budesonide in the treatment of patients with sinusitis can effectively enhance the therapeutic effect,significantly reduce the serum TIgE and ECP l

关 键 词：枸地氯雷他定 布地奈德 鼻窦炎 临床疗效 总免疫球蛋白E 嗜酸性粒细胞阳离子蛋白 

分 类 号：R765.41[医药卫生—耳鼻咽喉科]